GlaxoSmithKline News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.04.26	Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
15.04.26	GSK completes acquisition of 35Pharma Inc. (EN, GlaxoSmithKline)
12.04.26	GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers (EN, GlaxoSmithKline)
08.04.26	Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) (EN, GlaxoSmithKline)
30.03.26	Exdensur (depemokimab) approved in China for the treatment of severe asthma (EN, GlaxoSmithKline)
27.03.26	Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B (EN, GlaxoSmithKline)
23.03.26	GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan (EN, GlaxoSmithKline)
19.03.26	Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
13.03.26	GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18-49 years at increased risk (EN, GlaxoSmithKline)
10.03.26	GSK tops Antimicrobial Resistance (AMR) Benchmark Report (EN, GlaxoSmithKline)
09.03.26	GSK and Alfasigma announce agreement on worldwide rights for linerixibat (EN, GlaxoSmithKline)
03.03.26	GSK completes acquisition of RAPT Therapeutics (EN, GlaxoSmithKline)
26.02.26	Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B (EN, GlaxoSmithKline)
25.02.26	GSK enters agreement to acquire 35Pharma Inc. (EN, GlaxoSmithKline)
17.02.26	- (EN, GlaxoSmithKline)
17.02.26	Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (EN, GlaxoSmithKline)
17.02.26	GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows (EN, GlaxoSmithKline)
10.02.26	GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older (EN, GlaxoSmithKline)
06.02.26	Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD) (EN, GlaxoSmithKline)
04.02.26	GSK-Aktie nimmt zu: Umsatzprognose bis 2031 bestätigt (AWP) Der Pharmakonzern GSK hat dank eines unerwartet starken Schlussspurts im abgelaufenen Jahr besser abgeschnitten als gedacht.» mehr
04.02.26	Pharmakonzern GSK schlägt sich besser als erwartet - Ziele bestätigt (AWP)
04.02.26	GSK delivers strong 2025 performance and re-affirms long-term outlooks (EN, GlaxoSmithKline)
26.01.26	GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older (EN, GlaxoSmithKline)
23.01.26	Trelegy Ellipta approved in China for use in adults with uncontrolled asthma (EN, GlaxoSmithKline)
20.01.26	GSK enters agreement to acquire RAPT Therapeutics (EN, GlaxoSmithKline)
20.01.26	GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding (EN, GlaxoSmithKline)
07.01.26	GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission (EN, GlaxoSmithKline)
07.01.26	GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B (EN, GlaxoSmithKline)
06.01.26	Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps (EN, GlaxoSmithKline)
05.01.26	Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD) (EN, GlaxoSmithKline)
19.12.25	GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans (EN, GlaxoSmithKline)
16.12.25	Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma (EN, GlaxoSmithKline)
15.12.25	Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (EN, GlaxoSmithKline)
12.12.25	Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD) (EN, GlaxoSmithKline)
12.12.25	Depemokimab receives positive CHMP opinion for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (EN, GlaxoSmithKline)
12.12.25	GSK’s RSV vaccine, Arexvy, receives positive CHMP opinion for all adults 18 years and older (EN, GlaxoSmithKline)
11.12.25	WHO weist US-Aussagen zu Impfstoffen und Autismus zurück (AWP)
11.12.25	Blujepa (gepotidacin) approved by US FDA as oral option for treatment of uncomplicated urogenital gonorrhoea (uGC) (EN, GlaxoSmithKline)
10.12.25	GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA (EN, GlaxoSmithKline)
01.12.25	Britische Pharma-Exporte in die USA künftig zollfrei (AWP)
01.12.25	Britische Pharma-Exporte in die USA künftig zollfrei (AWP)
01.12.25	GSK data at ASH show potential to redefine outcomes for people living with blood cancers (EN, GlaxoSmithKline)
20.11.25	TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc. (EN, GlaxoSmithKline)
19.11.25	GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology (EN, GlaxoSmithKline)
18.11.25	GSK and Fleming Initiative scientists unite to target AMR with advanced AI (EN, GlaxoSmithKline)
07.11.25	GSK presents data from its advancing liver pipeline at AASLD 2025 (EN, GlaxoSmithKline)
29.10.25	Pharmakonzern GSK hebt nach unerwartet starkem Quartal nochmals Jahresziele an (AWP)
29.10.25	GSK delivers strong Q3 performance and upgrades 2025 guidance (EN, GlaxoSmithKline)
28.10.25	GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases (EN, GlaxoSmithKline)
28.10.25	GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives Orphan Drug Designation in the EU (EN, GlaxoSmithKline)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Nestle	80.75	6.90 %	K V
Roche Hldg PS	320.50	2.36 %	K V
Swisscom	666.00	1.52 %	K V
Kuehne+Nagel Int	194.25	1.17 %	K V
ABB	77.40	0.89 %	K V
CieFinRichemont	150.35	-1.09 %	K V
Alcon	59.66	-1.23 %	K V
Holcim	70.46	-1.37 %	K V
Logitech Intl	75.30	-2.69 %	K V
UBS Group	32.56	-2.92 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

GlaxoSmithKline Aktie VALOR 1102657 / ISIN GB0009252882

Nachrichten zu GlaxoSmithKline plc (GSK)

Aktien Top/Flop

Meistgelesene Nachrichten